Cargando…

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients under...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saltarella, Ilaria, Desantis, Vanessa, Melaccio, Assunta, Solimando, Antonio Giovanni, Lamanuzzi, Aurelia, Ria, Roberto, Storlazzi, Clelia Tiziana, Mariggiò, Maria Addolorata, Vacca, Angelo, Frassanito, Maria Antonia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017193/ https://www.ncbi.nlm.nih.gov/pubmed/31936617 http://dx.doi.org/10.3390/cells9010167

Ejemplares similares

MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance
por: Desantis, Vanessa, et al.
Publicado: (2020)

Uptake-Dependent and -Independent Effects of Fibroblasts-Derived Extracellular Vesicles on Bone Marrow Endothelial Cells from Patients with Multiple Myeloma: Therapeutic and Clinical Implications
por: Lamanuzzi, Aurelia, et al.
Publicado: (2023)

Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance
por: Melaccio, Assunta, et al.
Publicado: (2022)

The Landscape of lncRNAs in Multiple Myeloma: Implications in the “Hallmarks of Cancer”, Clinical Perspectives and Therapeutic Opportunities
por: Saltarella, Ilaria, et al.
Publicado: (2022)

MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease
por: Desantis, Vanessa, et al.
Publicado: (2021)

Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression
por: Saltarella, Ilaria, et al.
Publicado: (2021)

Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies
por: Reale, Antonia, et al.
Publicado: (2016)

Autophagy: A New Mechanism of Prosurvival and Drug Resistance in Multiple Myeloma
por: Desantis, V., et al.
Publicado: (2018)

Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
por: Lamanuzzi, Aurelia, et al.
Publicado: (2018)

Ion Channels in Multiple Myeloma: Pathogenic Role and Therapeutic Perspectives
por: Saltarella, Ilaria, et al.
Publicado: (2022)

Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma–Enhanced Angiogenesis: A Novel Therapeutic Target?()
por: Saltarella, Ilaria, et al.
Publicado: (2018)

High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
por: Solimando, Antonio Giovanni, et al.
Publicado: (2019)

Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients
por: Lamanuzzi, Aurelia, et al.
Publicado: (2016)

Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
por: Ria, Roberto, et al.
Publicado: (2020)

Microenvironment drug resistance in multiple myeloma: emerging new players
por: Di Marzo, Lucia, et al.
Publicado: (2016)

Anti-Angiogenic Activity of Drugs in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2023)

Cardiovascular Risk in Patients With Takayasu Arteritis Directly Correlates With Diastolic Dysfunction and Inflammatory Cell Infiltration in the Vessel Wall: A Clinical, ex vivo and in vitro Analysis
por: Cicco, Sebastiano, et al.
Publicado: (2022)

Gene expression profiling of normal thyroid tissue from patients with thyroid carcinoma
por: Ria, Roberto, et al.
Publicado: (2016)

Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin(®) protein MP0250: a preclinical study
por: Rao, Luigia, et al.
Publicado: (2018)

The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value
por: Desantis, Vanessa, et al.
Publicado: (2022)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies
por: Ria, Roberto, et al.
Publicado: (2014)

Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study
por: Cicco, Sebastiano, et al.
Publicado: (2020)

Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
por: Ria, Roberto, et al.
Publicado: (2012)

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2016)

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
por: Frerichs, Kristine A., et al.
Publicado: (2019)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
por: Pape, Luca Julius, et al.
Publicado: (2022)

Prognostic and Therapeutic Role of Angiogenic Microenvironment in Thyroid Cancer
por: Melaccio, Assunta, et al.
Publicado: (2021)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma
por: Choudhry, Priya, et al.
Publicado: (2019)

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
por: Perez de Acha, Olivia, et al.
Publicado: (2023)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

microRNAs as Biomarkers of Endothelial Dysfunction and Therapeutic Target in the Pathogenesis of Atrial Fibrillation
por: Desantis, Vanessa, et al.
Publicado: (2023)

Potential role of daratumumab in the treatment of multiple myeloma
por: Khagi, Yulian, et al.
Publicado: (2014)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
por: Plesner, Torben
Publicado: (2021)

Functional interplay between NF-κB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma
por: Mazzera, Laura, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ocpstktb5a7s940a4dqt220vfu